EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A Decade of Mitochondria‐Targeting Drugs in Cancer Treatment: Case Review on Mitochondria‐Targeting Curcumin or Mitocurcumin

Rahul Shah iD, Ryan Varghese iD, Harsh Anchan iD, Sanidhya Pai iD, Tanmay Zagade iD, Mitul Oswal iD, Sparsh Agarwal iD, Purab Sood iD, Gargi Digholkar iD, Abha Deshpande iD, Ravi Vamsi Peri iD, Pooja Tiwary iD und 2 weitere

Drug Development Research · 2025

DOI: 10.1002/ddr.70188 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, 2025. Verfasst von Rahul Shah und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy and Technology Management, Narsee Monjee Institute of Management Studies, Shirpur, Maharashtra, India. Hauptthemen laut MEDLINE: Curcumin, Mitochondria, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 289 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitochondrial targeting is of particular interest to researchers, as it presents as a personalized medicine approach in cancer cell metabolism and survival. By specifically targeting mitochondria, targeted therapies can disrupt energy production, induce apoptosis, and overcome drug resistance in cancer cells, potentially improving therapeutic outcomes. This review discusses the advancements in mitochondrial drug delivery over the last decade. It explores the potential of mitochondrial targeting using mitocurcumin (MTC), a novel small molecule curcumin analog that has been engineered to specifically target mitochondria in cancer cells, thereby augmenting its therapeutic efficacy. The antiproliferative activity of MTC demonstrates its ability to induce reactive oxygen species (ROS) production and promote oxidative stress‐mediated apoptosis, oxidative damage, and cellular senescence in diverse cancer cell lines, thereby enhancing its specificity for cancer cells. Despite these encouraging attributes, current research on MTC remains limited. Further comprehensive investigations are imperative to fully elucidate the efficacy and potential applications of mitochondrial targeting, especially MTC, in oncological therapeutics, including in vivo efficacy trials, pharmacokinetic profiling, toxicology studies, and combination therapy assessments. Although mitochondrial targeting presents a promising avenue for cancer therapy, rigorous scientific inquiry is essential to validate its clinical potential and optimize its therapeutic application for improved patient compliance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CurcuminMitochondriaNeoplasmsAntineoplastic AgentsHumansAnimalsDrug Delivery SystemsReactive Oxygen SpeciesApoptosis

Stichwörter der Autor:innen

cellular senescencechemical conjugationmitochondrial‐targetingmitocurcuminoxidative stresstargeted cancer therapy

Substanzen

CurcuminAntineoplastic AgentsReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Pharmaceutics, School of Pharmacy and Technology Management, Narsee Monjee Institute of Management Studies, Shirpur, Maharashtra, India.
  • Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Philadelphia, Pennsylvania, USA.
  • Chemical Biotechnology, Technische Universität München, Campus Straubing, Straubing, Germany.
  • Department of Biological Sciences, Indian Institute of Science, Bengaluru, Karnataka, India.
  • School of Pharmacy, National Forensic Sciences University, Gandhinagar, Gujarat, India.
  • Faculty of Bioscience Engineering, KU Leuven, Leuven, Belgium.

ORCID-Profile: Rahul Shah, Ryan Varghese, Harsh Anchan, Sanidhya Pai, Tanmay Zagade, Mitul Oswal, Sparsh Agarwal, Purab Sood, Gargi Digholkar, Abha Deshpande, Ravi Vamsi Peri, Pooja Tiwary, Krishil Oswal, Rohit Sharma

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Shah, R., Varghese, R., Anchan, H., Pai, S., Zagade, T., Oswal, M., Agarwal, S., Sood, P., Digholkar, G., Deshpande, A., Peri, R. V., Tiwary, P., Oswal, K., & Sharma, R. (2025). A Decade of Mitochondria‐Targeting Drugs in Cancer Treatment: Case Review on Mitochondria‐Targeting Curcumin or Mitocurcumin. Drug Development Research. https://doi.org/10.1002/ddr.70188

Vancouver

Shah R, Varghese R, Anchan H, Pai S, Zagade T, Oswal M, et al. A Decade of Mitochondria‐Targeting Drugs in Cancer Treatment: Case Review on Mitochondria‐Targeting Curcumin or Mitocurcumin. Drug Development Research. 2025. doi:10.1002/ddr.70188

BibTeX
@article{Shah2025,
  author = {Shah, Rahul and Varghese, Ryan and Anchan, Harsh and Pai, Sanidhya and Zagade, Tanmay and Oswal, Mitul and Agarwal, Sparsh and Sood, Purab and Digholkar, Gargi and Deshpande, Abha and Peri, Ravi Vamsi and Tiwary, Pooja and Oswal, Krishil and Sharma, Rohit},
  title = {A Decade of Mitochondria‐Targeting Drugs in Cancer Treatment: Case Review on Mitochondria‐Targeting Curcumin or Mitocurcumin},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70188}
}
Kostenlos starten →